tradingkey.logo
tradingkey.logo
Search

Atea Pharmaceuticals Inc

AVIR
Add to Watchlist
5.310USD
+0.130+2.51%
Close 09-11 16:00ET
426.69MMarket Cap
LossP/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+2.51%

5 Days

-8.92%

1 Month

+5.15%

6 Months

-12.95%

Year to Date

+48.74%

1 Year

+60.91%

Key Figures

5.230Open
5.410High
51.81KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.07%Turnover Ratio
5.180Prev. Close
5.180Low
274.35KTurnover
LossP/E Static
2.09P/B
0.00%Div Yield TTM
-47.95%ROA
6.45052wk High
0.20Volume Ratio
-168.38MNet Profit
80.20MShares
-2.1143EPS TTM
0.34Beta
-52.58%ROE
2.78052wk Low
4.25%Amplitude
--Gross Margin
426.69MMarket Cap
2.27Reward/Risk
3.14%Risk Rate
Recent
Transcripts
More news coming soon, stay tuned...

Atea Pharmaceuticals Inc's Score

0.10vs previous score
Forecast8.00
Financial Health6.09
Technical3.63
Valuation Dimensions7.96
Institutional Confidence7.00
Risk Assessment5.17

Media Coverage

Coverage Level

Very Low
Very High
Positive

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
8.500Target Price
+61.29%Upside Space
Current Rating2026-092026-082026-072026-062026-052026-042026-032026-02
Strong Buy11111111
Buy11111111
Hold11111111
Sell00000000
Strong Sell00000000

Atea Pharmaceuticals Inc Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D

Technical Indicators

Sell

Summary

Neutral

Moving Average

Neutral

Atea Pharmaceuticals Inc Latest Earnings Call Transcripts

Atea Pharmaceuticals (AVIR) Q2 2026 Earnings Call: C-BEYOND Meets Phase 3 Endpoint

Atea Pharmaceuticals’ Q2 2026 earnings call covered positive Phase 3 C-BEYOND HCV data, $219.5 million in cash and key 2027 regulatory milestones.

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-0.41/-0.56
Revenue / Forecast
--/0.00

Atea Pharmaceuticals Inc Profile

SectorBiotechnology & Medical Research
Ticker SymbolAVIR
Number of employees56
CountryUnited States of America

Ownership

ShareholdersProportion
Fidelity Management & Research Company LLC12.09%
BML Capital Management LLC8.82%
BlackRock Institutional Trust Company, N.A.7.79%
JPM Partner LLC6.39%
Shareholder TypesProportion
Investment Advisor44.60%
Investment Advisor/Hedge Fund12.77%
Hedge Fund11.88%
Individual Investor7.00%

FAQs

What is the current price of Atea Pharmaceuticals Inc (AVIR)?

The current price of Atea Pharmaceuticals Inc (AVIR) is 5.31.

What is the symbol of Atea Pharmaceuticals Inc?

The ticker symbol of Atea Pharmaceuticals Inc is AVIR.

What is the 52-week high of Atea Pharmaceuticals Inc?

The 52-week high of Atea Pharmaceuticals Inc is 6.45.

What is the 52-week low of Atea Pharmaceuticals Inc?

The 52-week low of Atea Pharmaceuticals Inc is 2.78.

What is the market capitalization of Atea Pharmaceuticals Inc?

The market capitalization of Atea Pharmaceuticals Inc is 426.69M.

Is Atea Pharmaceuticals Inc (AVIR) currently rated as Buy, Hold, or Sell?

According to analysts, Atea Pharmaceuticals Inc (AVIR) has an overall rating of Buy, with a price target of 8.50.

What is the Earnings Per Share (EPS TTM) of Atea Pharmaceuticals Inc (AVIR)?

The Earnings Per Share (EPS TTM) of Atea Pharmaceuticals Inc (AVIR) is -2.11.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.